http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Novel chimeric antigen receptors for the effective and safe treatment of NY-BR-1 positive breast cancer.
Jäger, D. (First author)DKFZ* ; Berger, A. (First author)DKFZ* ; Tuch, A.DKFZ* ; Luckner-Minden, C. ; Eurich, R. ; Hlevnjak, M. ; Schneeweiss, A. ; Lichter, P.DKFZ* ; Aulmann, S. ; Heussel, C.-P. ; Fremd, C. ; Harbottle, R.DKFZ* ; Zörnig, I. ; Schmidt, P. (Last author)DKFZ*
2024
Wiley
Hoboken, NJ
Keyword(s): Humans (MeSH) ; Breast Neoplasms: immunology (MeSH) ; Female (MeSH) ; Receptors, Chimeric Antigen: therapeutic use (MeSH) ; Receptors, Chimeric Antigen: immunology (MeSH) ; Treatment Outcome (MeSH) ; Receptors, Chimeric Antigen
Note: #EA:D120#LA:D420#
Contributing Institute(s):
- D120 Angewandte Tumor-Immunität (D120)
- B060 Molekulare Genetik (B060)
- DKTK HD zentral (HD01)
- DNA-Vektoren (D420)
- GMP-Einheit Zelluläre Therapie (D210)
Research Program(s):
- 314 - Immunologie und Krebs (POF4-314) (POF4-314)
Appears in the scientific report
2024
Database coverage:
;

;

;

; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 10 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection